The generic name for Namenda, a drug approved for treatment of moderate to severe Alzheimer's disease. 10

Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system. Memantine was developed by Merz and licensed to Forest for the U.S. and Lundbeck for selected European and international markets. Memantine is marketed under the brands Axura® and Akatinol® by Merz, Namenda® by Forest and Ebixa® by Lundbeck.

NDMA receptor antagonist being studied for the treatment of dementia in people with HIV.

A well-tolerated drug that acts as an NMDA receptor antagonist, preventing glutamate toxicity. It may slow the progression of HD.